ophthalmologytimes12h
ACELYRIN announces phase 2b/3 trial of izokibep did not meet primary endpoint, ceases further additional internal investment
The phase 2b/3 clinical trial (NCT05683496) evaluated izokibep versus placebo in non-infectious, non-anterior uveitis.
Hosted on MSN5d
AbbVie’s Phase III trial of Parkinson’s disease treatment meets primary endpoint
The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.
GlobalData on MSN5d
MSD’s trial of combination therapy for ovarian cancer meets primary endpoint
US-based pharmaceutical company MSD has published results from a Phase III trial of a potential combination therapy for ...
Cure Today13d
Tiragolumab Plus Tecentriq Misses Survival Endpoint for Lung Cancer Subset
The primary endpoint of overall survival was missed in the SKYSCRAPER-01 study assessing tiragolumab plus Tecentriq in some ...
Acsh.org6d
Moderna's mRNA Norovirus Vaccine Trials: To Hurl or Not to Hurl. That's the Endpoint.
Norovirus vaccines face significant hurdles, with virtually no success from past efforts from HilleVax and Vaxxart. But ...
Spruce Biosciences CAHmelia-204 study did not achieve primary efficacy endpoint
Spruce Biosciences (SPRB) “announced topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of ...
CervoMed announces RewinD-LB Phase 2b did not meet primary endpoint
CervoMed (CRVO) announced topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for the treatment of patients with dementia with Lewy bodies. DLB. The trial did not meet ...
PharmaTimes4d
Leriglitazone meets endpoint in trial for cerebral adrenoleukodystrophy
Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone met the primary endpoint in the NEXUS trial for ...
iTeos Therapeutics presents interim A2A-005 clinical trial data
Teos Therapeutics (ITOS) announced the presentation of clinical, translational, and preclinical data from its adenosine A2A receptor ...